Welcome to our dedicated page for CUMBERLAND PHARMACEUTICALS SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Cumberland Pharmaceuticals Inc. executed a major strategic shift, completing on July 1, 2026 the sale of its FDA‑approved branded products to Apotex for $100 million in cash, plus up to $9 million of inventory reimbursement and approximately $2 million for transition services. The company will now operate as a development‑stage biopharmaceutical business focused on its ifetroban clinical programs and early‑stage candidates at Cumberland Emerging Technologies.
For the six months ended June 30, 2026, net revenues from continuing operations were $330,308 and the net loss from continuing operations was $5,962,447. Including discontinued operations, net loss attributable to common shareholders was $7,566,016, compared with net income of $516,328 in the prior‑year period, reflecting weaker results from the divested brand portfolio.
Cash and cash equivalents were $3,862,402 at June 30, 2026, before receipt of Apotex proceeds and repayment of the $5.2 million revolving credit facility. Management states that cash on hand, the $100 million transaction proceeds and inventory reimbursement will fund operations for at least twelve months. The board declared a special cash dividend of $1.50 per share, totaling $22.5 million, and authorized a new $5 million share repurchase program.
Cumberland Pharmaceuticals Inc. reported results for the three and six months ended June 30, 2026 and described a major strategic shift following the closing of its Strategic Transaction with Apotex Health. Apotex acquired Cumberland’s portfolio of FDA-approved brands and related commercial organization for $100 million in cash at closing, plus $11 million in funding for inventory and transition services, as Cumberland transitions to a development-stage biopharmaceutical company focused on rare diseases and other unmet needs.
The Board declared a $1.50 per-share special cash dividend, paid July 31, 2026 to shareholders of record July 23, 2026, after determining the company would retain significant liquidity for its pipeline and operations. For Q2 2026, the loss from continuing operations was $3.1 million, and including discontinued operations the net loss was $4.1 million.
At June 30, 2026, total assets were $62.9 million, including $3.9 million in cash and cash equivalents, with liabilities of $45.8 million and shareholders’ equity of $17.4 million$5.2 million payment and continues to advance four Phase 2 ifetroban programs, including updated Duchenne muscular dystrophy and cancer metastasis data.
Cumberland Pharmaceuticals Inc. authorized and declared a special cash dividend of $1.50 per share on its common stock, payable on or about July 31, 2026 to shareholders of record at the close of business on July 23, 2026. The board also approved a new open‑market share repurchase program authorizing up to $5 million of common stock over time, replacing the prior authorization.
These capital return actions follow a strategic transaction with Apotex Health Corp., under which Cumberland received $100 million in cash at closing for its line of FDA‑approved products and expects up to an additional $11 million tied to product inventory and transitional support services. After tax analysis and updated financial projections indicated greater net cash than first projected, the board assessed future cash needs and designated excess capital for the dividend and repurchase, while several directors plan new share purchase arrangements.
Cumberland retains its portfolio of product candidates and majority stake in Cumberland Emerging Technologies Inc. and will focus resources on late‑stage development of ifetroban for serious rare diseases, including Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and high‑risk solid tumors, supported by multiple Phase II studies and U.S. FDA designations.
Cumberland Pharmaceuticals has closed a strategic asset sale to Nuvo Pharmaceuticals and Apotex affiliates, receiving cash consideration of $100 million for its FDA‑approved branded products, including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ, plus related equity interests.
The company used part of the proceeds to terminate and fully repay about $5.3 million outstanding under its revolving credit agreement, releasing associated liens. Pro forma as of March 31, 2026, cash and cash equivalents rise to roughly $110.2 million, with shareholders’ equity increasing to about $81.4 million, while the disposed operations will be treated as discontinued operations.
Cumberland is retaining its ifetroban product candidates and majority stake in Cumberland Emerging Technologies, and will focus on late‑stage development programs in rare and serious diseases including Duchenne muscular dystrophy, systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis.
Cumberland Pharmaceuticals Inc. held a special meeting of shareholders to vote on a proposal tied to a strategic transaction with Apotex Inc. involving the company’s FDA-approved commercial products and related assets.
Shareholders approved authorizing and approving the asset sale, which may be deemed under Tennessee law to be a sale of substantially all of the company’s property and assets outside the usual course of business. Of 14,983,107 common shares entitled to vote as of the record date, 10,509,626 were present, representing a 70.14% quorum. The proposal received 10,492,455 votes in favor, 15,904 against, and 1,267 abstentions, meaning 70.03% of all outstanding shares and 99.84% of votes cast supported the transaction.
Cumberland Pharmaceuticals Inc. requests shareholder approval to sell its FDA‑approved commercial products and related assets to an affiliate of Apotex pursuant to an Asset Purchase Agreement dated April 22, 2026. The agreement provides for $100,000,000 in cash at closing. The Company will retain its ifetroban product candidates and Cumberland Emerging Technologies and intends to use proceeds to fund retained development programs and working capital. The Board unanimously recommends a vote FOR the Transaction at a special meeting on June 24, 2026. The closing is conditioned on shareholder approval, specified consents, absence of a material adverse effect, and other customary conditions, with an Outside Date of August 20, 2026. The Agreement includes indemnities, caps, a $4,000,000 termination fee framework, and up to $10,000,000 in contingent Vibativ milestones.
The board of Cumberland Pharmaceuticals Inc. is asking shareholders to approve an asset sale to an affiliate of Apotex under an Asset Purchase Agreement dated April 22, 2026. Under the agreement Apotex will acquire Cumberland’s U.S. FDA‑approved commercial products for $100,000,000 in cash at closing. Cumberland will retain its ifetroban clinical programs and majority-owned Emerging Technologies subsidiary and intends to use proceeds to fund those retained development activities. Certain directors and officers holding approximately 41% of outstanding shares have entered Voting and Support Agreements to vote in favor. The transaction is subject to shareholder approval, third‑party consents, absence of a Material Adverse Effect, customary closing conditions and an Outside Date of August 20, 2026. The board unanimously recommends a FOR vote.
Cumberland Pharmaceuticals reported a weak quarter while outlining a transformative strategic deal. For the three months ended March 31, 2026, net revenues were $9.1 million and the company posted a net loss of $3.3 million, compared with net income of $1.2 million a year earlier. Operating cash flow remained positive at $0.4 million, but working capital turned slightly negative, with current liabilities exceeding current assets by about $1.7 million.
Subsequent to quarter-end, Cumberland agreed to sell the assets and U.S. rights to its portfolio of FDA‑approved brands to an affiliate of Apotex Inc. for $100 million in cash, subject to shareholder approval and closing conditions. The company will retain its ifetroban development programs and Cumberland Emerging Technologies, transitioning toward a development‑stage profile. The agreement also provides for a potential Vibativ milestone payment, up to $9 million of inventory reimbursement one year after closing, and monthly transition‑services fees of $150,000 plus certain reimbursed costs.
Cumberland Pharmaceuticals reported first quarter 2026 net revenues of $9.1 million, with management noting this was a 5% increase versus the prior year period after excluding a $3 million milestone received in 2025. The quarter ended with total assets of $71.0 million, liabilities of $49.7 million and shareholders’ equity of $21.6 million.
The company recorded a net loss of $3.3 million, or $0.22 per shareadjusted loss of $1.9 million, or $0.13 per share. Total operating expenses were $12.3 million.
Cumberland also highlighted a pending Strategic Transaction with Apotex, under which Apotex will acquire Cumberland’s portfolio of FDA‑approved brands for $100 million in cash, subject to shareholder approval and customary conditions. Cumberland will retain its ifetroban development programs and its majority interest in Cumberland Emerging Technologies, positioning the company as a development‑stage biopharmaceutical organization focused on orphan and other high‑value candidates.
Cumberland Pharmaceuticals Inc. reported the results of its annual shareholder meeting held in Nashville, Tennessee on April 21, 2026. Shareholders elected Class I directors Kenneth J. Krogulski and Caroline R. Young, each receiving over 98% of votes cast, with Krogulski supported by 9,561,336 votes and Young by 9,479,023 votes.
Shareholders also ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for the year ending December 31, 2026, with 12,714,116 votes in favor. An advisory vote approved the compensation of named executive officers, and another advisory vote indicated a strong preference to hold this say‑on‑pay vote every three years, supported by 7,844,848 votes.